Napo Pharmaceuticals, Inc.’s Post

CAR-T therapy in CLL could be an area where biomarkers would be helpful.  The FDA recently approved lisocabtagene maraleucel in CLL/SLL after at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor.  Looking at the published data of only the 49 patients who received lisocabtagene maraleucel at the FDA-approved dose, 9 patients (18.4%) had a complete response (CR), and those patients, at median follow-up of 20.8 months, were all progression-free.  12 patients (24.5%) had a partial response (PR) or nodular partial response or remission (nPR), and those patients had median PFS of 26.2 months,   Lisocabtagene maraleucel also appears to have an increased risk of adverse events in CLL. For example, cytokine release syndrome (CRS) occurred in 83% (74/89) of all patients, including grade 3 CRS in 9% of patients, much higher than in the DLBCL patients.  In the BRUIN trial, pirtobrutinib had a median PFS of 16.8 months in the BTK/BCL2 refractory population.  However, pirtobrutinib had zero patients with a CR.   Given the cost and increased adverse events of lisocabtagene maraleucel, it would be nice to have biomarkers that could identify which patients could achieve a CR.  If the CR data holds up and we are curing patients, we want to be able to do so - but it would be difficult to recommend this to all patients to whom this indication would apply to. #breyanzi #jaypirca #cll https://lnkd.in/eaii6qvv

Tune in to learn more about why Cereno Scientific is such an interesting investment case and to hear Rahul Dr. Agrawal explain the disease-modifying properties of CS1 in pulmonary arterial hypertension:

Take a 4 minute break ☕️to read this article 📰 and learn more about #SIRT with #personalisedosimetry and their positive impact on treatment landscape for #HCC patients. OncLive

“Innovative Penny Stocks Paving the Way Across Diverse Sectors: ADHC, BIEI, ADIA, SPZI, HALB”: These five companies under a penny are driving innovation and growth across diverse sectors, positioning themselves for substantial shareholder value and long-term success. American Diversified Holdings Corporation (OTC: ADHC) has acquired GlucoGuard, an AI-driven device for managing nocturnal hypoglycemia in diabetic … Continue reading → #Business #FinancialMarket #HealthMedicine #Sports #Technology

C-Path's Cure Drug Repurposing Collaboratory, and the CURE ID team will be onsite at the International Drug Repurposing Conference 2024 (#iDR24): Bridging boundaries for Innovative Drug Repurposing this week where key leaders in drug repurposing will unite. Co-organized by REMEDi4ALL, Beacon for Rare Diseases and MeRIT, the conference showcases how patient communities, researchers, industry and health authorities can benefit from cutting-edge drug repurposing. The agenda follows three topical paths in parallel: · Cancer · Rare Disease · Methodologies Find out more about the speakers, location, details here: https://lnkd.in/eRtYcAmZ Smith Heavner, PhD, RN | Marco Schito | Heather Stone | Shira Strongin | Keyla Tumas #CPath #REMEDi4ALL #Beacon #MeRIT #drugrepurposing #patientadvocacy

Despite recent IPO fluctuations, American Healthcare REIT, Fortegra Group, and Fractyle Health forge ahead, indicating resilience in the market. American Healthcare REIT leads with an impressive $869 million, showcasing ongoing investor confidence. Fortegra Group and Fractyle Health, though smaller in scale, contribute to the diverse offerings. The varied IPO performances of CG Oncology and BrightSpring Health underline the market's unpredictability. Amer Sports adds to the mix, emphasizing sustained IPO activity. While challenges persist, these healthcare, insurance, and biotech ventures demonstrate a collective commitment to navigating the dynamic IPO landscape, seizing opportunities, and adapting to market dynamics. #biotech #ipo #healthcareinvesting

**Only Put Off Until Tomorrow What You Are Willing to Die Having Left Undone** Shares of Hologic HOLX are soaring, trading near their 52-week high of $84.67. Closing at $80.99 on Thursday, the stock is just 4.3% below its peak. Over the past three months, this women's health company has experienced impressive gains of 8.5%, outpacing the industry's growth of 2%. With HOLX stock performing so strongly, now is the time to take action and seize this opportunity to grow your Health Savings Account (HSA). Don't delay, as hesitation can lead to the fear of missing out (FOMO). Investing in HOLX can provide a significant boost to your HSA, ensuring the long-term financial security of yourself and your family. By allocating a portion of your HSA funds into this thriving healthcare sector, you not only invest in your financial well-being but also in the well-being of countless individuals who benefit from Hologic's women's health innovations. #HSA #Investing #Healthcare #Health #Family #Wellness 📈🏥🌟👨👩👧👦💪🔥 So don't wait any longer, take charge of your financial future, and invest in HOLX today!

Proud to announce that Mermaid Bio GmbH and their CEO Ranja Salvamoser will be presenting at Meet the DONs Virtual Event on the 24th of October. Sophisticated investors, decision makers, and opportunities are all brought together by this special online experience. Due in part to COVID, we have welcomed over 1,500 virtual attendees since our launch in 2020. A true meeting place for CEO's, Founders, decision makers and sophisticated investors. Mermaid Bio GmbH’s Intrabodies represent a novel precision-medicine approach that can tackle notoriously difficult targets and is piloted directly to the tissue of interest to avoid damaging side effects. Intrabodies The power of antibodies and targeted drug delivery, wrapped in one. By pairing antibodies with intracellular delivery, Intrabodies bring the strength of antibodies into diseased cells, without damaging healthy tissues. Beyond giving patients new hope, our purpose is to restore their quality of life If you are a Founder, CEO or sophisticated investor register for free with this link - https://lnkd.in/eRMU3CEH Are you a healthcare business seeking funding if so, feel free to submit your opportunity to our network via this link - https://lnkd.in/ep8Bqsb8

The latest DDW Sitting Down With sponsored vodcast is now available. It features Dr Adriano Flora, Director of Business Development at The Jackson Laboratory. In this vodcast, Dr Flora discusses: - Alternatives to non-human primates - Key benefits of this - What impact will they have on the future of drug development - Key breakthroughs in recent years in this field  - How have these impacted future success - Challenges in the clinic that must be overcome to ensure success   https://lnkd.in/eqtWJ2Jv #DrugDiscovery #DrugDevelopment #Vodcast

Hamlet BioPharma - I just love this company, their research and to be part of the journey by investing in the stock. Investing in research companies within the pharmaceutical industry often involves a high level of risk, and I usually am cautious about it. However, Hamlet BioPharma continues to deliver brilliant results and presents positive news almost every week. Check out the company and listen to the great MSQ webinar where Catharina Svanborg, founder and chairman of Hamlet BioPharma, presents the company and the studies. Keep up the good work Team Hamlet! Hamlet Bio Pharma can be found where stocks are traded… for example, Nordnet and Avanza. Disclaimet: As always…This is by no means a recomendation to invest and there are always risks involved by doing so. #hamletbiopharma #Nordnet #Avanza